Shandling AH, Ellestad MH, Hart GB, Crump R, Marlow D, Van Natta B, Messenger JC, Strauss M, Stavitsky Y, et al.
American heart journal. Date of publication 1997 Sep 1;volume 134(3):544-50.
1. Am Heart J. 1997 Sep;134(3):544-50.
Hyperbaric oxygen and thrombolysis in myocardial infarction: the "HOT MI" pilot
study.
Shandling AH(1), Ellestad MH, Hart GB, Crump R, Marlow D, Van Natta B, Messenger
JC, Strauss M, Stavitsky Y.
Author information:
(1)Department of Cardiology, Long Beach Memorial Medical Center, CA 90801, USA.
Comment in
Am Heart J. 1998 Oct;136(4 Pt 1):749.
Hyperbaric oxygen treatment (HBO) in combination with thrombolysis has been
demonstrated to salvage myocardium in acute myocardial infarction in the animal
model. Therefore a randomized pilot trial was undertaken to assess the safety and
feasibility of this treatment in human beings. Patients with an acute myocardial
infarction (AMI) who received recombinant tissue plasminogen activator (rTPA)
were randomized to treatment with HBO combined with rTPA or rTPA alone. Sixty-six
patients were included for analysis. Forty-three patients had inferior AMIs
(difference not significant) and the remainder had anterior AMIs. The mean
creatine phosphokinase level at 12 and 24 hours was reduced in the patients given
HBO by approximately 35% (p = 0.03). Time to pain relief and ST segment
resolution was shorter in the group given HBO. There were two deaths in the
control group and none in those treated with HBO. The ejection fraction on
discharge was 52.4% in the group given HBO compared with 47.3% in the control
group (difference not significant). Adjunctive treatment with HBO appears to be a
feasible and safe treatment for AMI and may result in an attenuated rise in
creatine phosphokinase levels and more rapid resolution of pain and ST segment
changes.
DOI: 10.1016/s0002-8703(97)70093-0
PMID: 9327714 [Indexed for MEDLINE]
